MY139525A - Polymorphic forms of a gabaa agonist. - Google Patents

Polymorphic forms of a gabaa agonist.

Info

Publication number
MY139525A
MY139525A MYPI20050253A MYPI20050253A MY139525A MY 139525 A MY139525 A MY 139525A MY PI20050253 A MYPI20050253 A MY PI20050253A MY PI20050253 A MYPI20050253 A MY PI20050253A MY 139525 A MY139525 A MY 139525A
Authority
MY
Malaysia
Prior art keywords
polymorphic forms
gabaa agonist
gabaa
agonist
new crystalline
Prior art date
Application number
MYPI20050253A
Other languages
English (en)
Inventor
Vincent Brett Cooper
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY139525(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MY139525A publication Critical patent/MY139525A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20050253A 2004-01-30 2005-01-24 Polymorphic forms of a gabaa agonist. MY139525A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist

Publications (1)

Publication Number Publication Date
MY139525A true MY139525A (en) 2009-10-30

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20050253A MY139525A (en) 2004-01-30 2005-01-24 Polymorphic forms of a gabaa agonist.

Country Status (34)

Country Link
US (2) US7262300B2 (enExample)
EP (2) EP2042505A1 (enExample)
JP (1) JP4917440B2 (enExample)
KR (1) KR101210361B1 (enExample)
CN (1) CN1914212B (enExample)
AR (1) AR047511A1 (enExample)
AT (1) ATE414088T1 (enExample)
AU (1) AU2005209473B2 (enExample)
BR (1) BRPI0506858A (enExample)
CA (1) CA2554536C (enExample)
CO (1) CO5700743A2 (enExample)
CY (1) CY1108647T1 (enExample)
DE (1) DE602005010975D1 (enExample)
DK (1) DK1713813T3 (enExample)
DO (1) DOP2005000013A (enExample)
EA (1) EA009413B1 (enExample)
EC (1) ECSP066735A (enExample)
ES (1) ES2314613T3 (enExample)
GB (2) GB0402118D0 (enExample)
HR (1) HRP20080614T3 (enExample)
IL (1) IL176863A0 (enExample)
MA (1) MA28364A1 (enExample)
MX (1) MXPA06008595A (enExample)
MY (1) MY139525A (enExample)
NO (1) NO20063843L (enExample)
NZ (1) NZ548191A (enExample)
PE (1) PE20050769A1 (enExample)
PL (1) PL1713813T3 (enExample)
PT (1) PT1713813E (enExample)
SI (1) SI1713813T1 (enExample)
TW (1) TWI345972B (enExample)
UA (1) UA87487C2 (enExample)
WO (1) WO2005073237A2 (enExample)
ZA (1) ZA200605307B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
BRPI0520588B8 (pt) 2005-09-28 2021-05-25 Auris Medical Ag uso de composições farmacêuticas para o tratamento de doenças do ouvido interno
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
WO2001022941A1 (en) 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
MXPA03010610A (es) 2001-05-18 2004-04-02 Lonza Ag Metodo para la preparacion de formulaciones solidas de 3-hidroxi-3-metilbutirato de sodio.
CZ20033269A3 (en) 2001-05-21 2004-03-17 H. Lundbeck A/S Granular preparations of gaboxadol
AU2002333157A1 (en) * 2002-09-03 2004-03-29 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP2145620A3 (en) 2003-06-25 2010-03-17 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2572302A1 (en) 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) * 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
EP1863808A1 (en) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL

Also Published As

Publication number Publication date
DOP2005000013A (es) 2005-08-15
CN1914212B (zh) 2010-10-06
HK1096547A1 (en) 2007-06-01
NZ548191A (en) 2010-04-30
PE20050769A1 (es) 2005-10-04
HRP20080614T3 (en) 2009-01-31
US20070259912A1 (en) 2007-11-08
SI1713813T1 (sl) 2009-02-28
PL1713813T3 (pl) 2009-04-30
KR101210361B1 (ko) 2012-12-10
TWI345972B (en) 2011-08-01
CN1914212A (zh) 2007-02-14
CY1108647T1 (el) 2014-04-09
GB0501847D0 (en) 2005-03-09
US7262300B2 (en) 2007-08-28
EA200601404A1 (ru) 2006-12-29
ZA200605307B (en) 2007-11-28
CA2554536C (en) 2012-09-18
JP4917440B2 (ja) 2012-04-18
PT1713813E (pt) 2008-12-26
WO2005073237A3 (en) 2005-10-20
BRPI0506858A (pt) 2007-05-29
UA87487C2 (ru) 2009-07-27
EA009413B1 (ru) 2007-12-28
ECSP066735A (es) 2006-10-31
EP2042505A1 (en) 2009-04-01
IL176863A0 (en) 2006-10-31
CO5700743A2 (es) 2006-11-30
KR20070007070A (ko) 2007-01-12
MXPA06008595A (es) 2006-08-28
AU2005209473B2 (en) 2010-03-04
MA28364A1 (fr) 2006-12-01
NO20063843L (no) 2006-08-29
US20050171142A1 (en) 2005-08-04
EP1713813A2 (en) 2006-10-25
JP2007519697A (ja) 2007-07-19
TW200534856A (en) 2005-11-01
US8236958B2 (en) 2012-08-07
WO2005073237A2 (en) 2005-08-11
DE602005010975D1 (de) 2008-12-24
EP1713813B1 (en) 2008-11-12
AR047511A1 (es) 2006-01-25
GB2410434A (en) 2005-08-03
ES2314613T3 (es) 2009-03-16
ATE414088T1 (de) 2008-11-15
GB0402118D0 (en) 2004-03-03
CA2554536A1 (en) 2005-08-11
DK1713813T3 (da) 2009-02-16
AU2005209473A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
MY139525A (en) Polymorphic forms of a gabaa agonist.
IL188781A (en) A method for improving synchronization
GB2452425B (en) Methods of using well testing tools
GB0525936D0 (en) Methods of analysing apparatus
SG141461A1 (en) Method for producing annelated piperazin-2-one derivatives and intermediates of said method
IL178404A0 (en) Methods and apparatus for searching a list of pilot signals
EP2243045A4 (en) Method for enhancing low frequency output of impulsive type seismic energy sources for use while drilling
PL1778710T3 (pl) Pochodne tanaprogetu, metabolity i ich zastosowania
TW200616633A (en) CCI-779 derivatives and methods of making same
EP1969012A4 (en) PROCESS FOR PREPARING HYDROXYALKYL ALKYL CELLULOSE ETHERS WITH HIGH PURITY
SG142306A1 (en) Methods for neuroprotection
KR100519083B1 (ko) 김치 발효용 스타터 및 이를 사용한 김치 제조방법
SG144920A1 (en) Method and intermediates for the preparation of derivatives of n-(1- benzhydrylazetidin-3-yl)-n-phenylmethylsulphonamide
EP1930419A4 (en) ENZYME PROCESS
EP1880995A4 (en) METHOD OF SYNTHESIZING AN INDOLE DERIVATIVE COMPRISING A PIPERIDINE CYCLE
EP1797101A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF LEVOFLOXACIN HEMIHYDRATE
MD2577F1 (en) Method of abdominal wing peritonization after hemicolectomy
PL368150A1 (en) Method for obtaining polyetheroles with carbazole ring
ZA200600906B (en) Method of producing an enzyme mixture
AU2004905143A0 (en) Method of screening
PL368151A1 (en) Method for obtaining two-function polyetheroles with carbazole ring
GB0500417D0 (en) Method of mutagenesis
AU2007901452A0 (en) Method of screening
AU2007904304A0 (en) Method of screening
PL377951A1 (pl) Nowa pochodna N-alkilobis(tiofeno)karbazolu i sposób jej wytwarzania